Cargando…
Innovative oncology products: time to revisit the strategy development?
Autor principal: | Krendyukov, Andriy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830456/ https://www.ncbi.nlm.nih.gov/pubmed/31749992 http://dx.doi.org/10.1136/esmoopen-2019-000571 |
Ejemplares similares
-
Early Access Provision for Innovative Medicinal Products in Oncology: Challenges and Opportunities
por: Krendyukov, Andriy
Publicado: (2020) -
Extrapolation concept at work with biosimilar: a decade of experience in oncology
por: Krendyukov, Andriy, et al.
Publicado: (2018) -
The ESMO position paper on biosimilars in oncology: enhancing the provision of accurate education and information
por: Schiestl, Martin, et al.
Publicado: (2017) -
Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies
por: Krendyukov, Andriy, et al.
Publicado: (2019) -
Revisiting and innovating pharmacology education
por: Desai, Chetna
Publicado: (2016)